These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28656383)

  • 41. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
    Verschraegen CF; Czok S; Muller CY; Boyd L; Lee SJ; Rutledge T; Blank S; Pothuri B; Eberhardt S; Muggia F
    Ann Oncol; 2012 Dec; 23(12):3104-3110. PubMed ID: 22851407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
    Perez-Fidalgo JA; Cortés A; Guerra E; García Y; Iglesias M; Bohn Sarmiento U; Calvo García E; Manso Sánchez L; Santaballa A; Oaknin A; Redondo A; Rubio MJ; González-Martín A
    ESMO Open; 2021 Aug; 6(4):100212. PubMed ID: 34329939
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Lisyanskaya AS; Makhson AN; Rolski J; Gorbounova VA; Ghatage P; Bidzinski M; Shen K; Ngan HY; Vergote IB; Nam JH; Park YC; Lebedinsky CA; Poveda AM
    J Clin Oncol; 2010 Jul; 28(19):3107-14. PubMed ID: 20516432
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).
    Lee YJ; Seol A; Lee M; Kim JW; Kim HS; Kim K; Suh DH; Kim S; Kim SW; Lee JY
    In Vivo; 2022; 36(4):1949-1958. PubMed ID: 35738633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.
    Rapoport BL; Vorobiof DA; Slabber C; Alberts AS; Hlophe HS; Mohammed C
    Int J Gynecol Cancer; 2009 Aug; 19(6):1137-41. PubMed ID: 19820382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
    Fuh KC; Bookman MA; Liu JF; Coleman RL; Herzog TJ; Thaker PH; Monk BJ; Anderson R; McIntyre G; Rangwala R; Moore KN
    Gynecol Oncol; 2021 Nov; 163(2):254-261. PubMed ID: 34474927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.
    Witteveen PO; van der Mijn KJ; Los M; Kronemeijer RH; Groenewegen G; Voest EE
    Neoplasia; 2010 Nov; 12(11):941-5. PubMed ID: 21076619
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
    du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
    Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
    Hamanishi J; Takeshima N; Katsumata N; Ushijima K; Kimura T; Takeuchi S; Matsumoto K; Ito K; Mandai M; Nakai H; Sakuragi N; Watari H; Takahashi N; Kato H; Hasegawa K; Yonemori K; Mizuno M; Takehara K; Niikura H; Sawasaki T; Nakao S; Saito T; Enomoto T; Nagase S; Suzuki N; Matsumoto T; Kondo E; Sonoda K; Aihara S; Aoki Y; Okamoto A; Takano H; Kobayashi H; Kato H; Terai Y; Takazawa A; Takahashi Y; Namba Y; Aoki D; Fujiwara K; Sugiyama T; Konishi I
    J Clin Oncol; 2021 Nov; 39(33):3671-3681. PubMed ID: 34473544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.
    Kudoh K; Takano M; Kouta H; Kikuchi R; Kita T; Miyamoto M; Watanabe A; Kato M; Goto T; Kikuchi Y
    Gynecol Oncol; 2011 Aug; 122(2):233-7. PubMed ID: 21601912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
    Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
    Romero I; Mallol P; Santaballa A; Del Campo JM; Mori M; González-Santiago S; Casado A; Vicente D; Ortega E; Herrero A; Guerra E; Barretina-Ginesta P; Rubio MJ; Martínez A; Bover I; Vidal L; Arcusa Á; Martín L; García Y; González-Martín A
    Anticancer Drugs; 2019 Jul; 30(6):628-635. PubMed ID: 31008727
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
    Marth C
    Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience.
    Moriceau G; Rivoirard R; Méry B; Vallard A; Pacaut C; Trone JC; Espenel S; Bosacki C; Jacquin JP; Magné N
    Chemotherapy; 2016; 61(3):122-6. PubMed ID: 26752402
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
    Gladieff L; Ferrero A; De Rauglaudre G; Brown C; Vasey P; Reinthaller A; Pujade-Lauraine E; Reed N; Lorusso D; Siena S; Helland H; Elit L; Mahner S
    Ann Oncol; 2012 May; 23(5):1185-1189. PubMed ID: 21976386
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
    Colombo N; Hardy-Bessard AC; Ferrandina G; Marth C; Romero I
    Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):11-19. PubMed ID: 27797622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
    Marth C; Vergote I; Scambia G; Oberaigner W; Clamp A; Berger R; Kurzeder C; Colombo N; Vuylsteke P; Lorusso D; Hall M; Renard V; Pignata S; Kristeleit R; Altintas S; Rustin G; Wenham RM; Mirza MR; Fong PC; Oza A; Monk BJ; Ma H; Vogl FD; Bach BA
    Eur J Cancer; 2017 Jan; 70():111-121. PubMed ID: 27914241
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
    Weber B; Lortholary A; Mayer F; Bourgeois H; Orfeuvre H; Combe M; Platini C; Cretin J; Fric D; Paraiso D; Pujade-Lauraine E
    Anticancer Res; 2009 Oct; 29(10):4195-200. PubMed ID: 19846972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
    Liu Y; Ren Z; Xu S; Bai H; Ma N; Wang F
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):645-51. PubMed ID: 25599660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.